Venus Concept Announces CE Mark for Venus Versa Pro in Europe
February 22 2024 - 6:30AM
Venus Concept Inc. (“Venus Concept” or the
“Company”) (NASDAQ: VERO), a global medical aesthetic
technology leader, today announced that it has received the CE Mark
from DEKRA Certification B.V. to market the Venus Versa Pro
system in the European Union. This follows the Company’s
announcement on November 1, 2023 regarding the commercial launch of
the device in the United States.
The Venus Versa Pro incorporates Venus Concept’s
latest advancements in fractional skin resurfacing, enabling
enhanced ablation and coagulation to achieve optimal results when
treating a wide range of skin conditions including acne scars, skin
texture, and stretch marks. It also provides customers in the
European Union the ability to incorporate these advancements into
unique protocols like “Tribella”, offering a complete skin
rejuvenation solution.
“Receiving the CE Mark for Venus Versa Pro reflects
our continued commitment to bringing our latest and most innovative
products to the international aesthetic markets in parallel with
our restructuring efforts,” said Dr. Hemanth Varghese, President
and Chief Operating Officer of Venus Concept. “Venus Versa Pro
builds on the successful Venus Versa system, with over 2,200
systems installed globally. It is a multi-modal system that
incorporates the breadth of Venus Concept’s technologies for
clinicians to address the growing needs of the European
customer.”
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Any statements contained herein that are not
of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify these statements by words such as
such as “anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “should,” “could,” “estimates,”
“predicts,” “potential,” and other similar expressions that are
predictions of or indicate future events and future trends. These
forward-looking statements are based on current expectations,
estimates, and projections about our business, and the industry in
which the Company operates and management's beliefs and assumptions
and are not guarantees of future performance or developments and
involve known and unknown risks, uncertainties, and other factors
that are in some cases beyond our control. As a result, any or all
of our forward-looking statements in this communication may turn
out to be inaccurate. Factors that could materially affect our
business operations and financial performance and condition
include, but are not limited to, those risks and uncertainties
described under Part II Item 1A—“Risk Factors” in our Quarterly
Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31,
2022. You are urged to consider these factors carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on the forward-looking statements. The
forward-looking statements are based on information available to us
as of the date of this communication. Unless required by law, the
Company does not intend to publicly update or revise any
forward-looking statements to reflect new information or future
events or otherwise.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 12
direct markets. Venus Concept's product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus
Concept's hair restoration systems include NeoGraft® and the ARTAS
iX® Robotic Hair Restoration system. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From May 2024 to Jun 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Jun 2023 to Jun 2024